Torrent Pharma gets one USFDA observation for Pithampur facility
Written By : Ruchika Sharma
Medically Reviewed By : Kamal kant gupta
Published On 2024-09-19 12:00 GMT | Update On 2024-09-19 12:00 GMT
Advertisement
Ahmedabad: Torrent Pharma has announced that the United States Food & Drug Administration (USFDA) has issued one observation at the end of a routine GMP inspection at the Company's Formulation manufacturing facility located at Pithampur, Madhya Pradesh.
The inspection was conducted between 16-Sep-24 to 20-Sep-24.
"At the end of the Inspection, the Agency issued a Form FDA 483 with one observation which is procedural in nature. We will respond to the USFDA within the prescribed time-frame and will work in close collaboration with the Agency to address the observation at the earliest possible time," Dr Reddy's Labs stated.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.